The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies.
|Slideshows|November 10, 2017
FDA Cancer Drug Approvals in 2017
Author(s)Cancer Network Editors
This slide show highlights some of this year’s FDA approvals of cancer treatments, including new therapies and indications for breast cancer, lung cancer, and various blood cancers, as well as the first approval based not on disease site but by tumor marker.
Advertisement
Advertisement
Related to this article
“Cardiovascular assessment should begin when the patient is being selected for treatment, not after the toxicity emerges,” said Faisal Mehmud, MD, MRCP.
The FDA has approved lirafugratinib for advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement based on the phase 1/2 ReFocus trial.
Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
In the LINKER-SMM1 trial, single-agent linvoseltamab produced a 100% overall response rate among evaluable patients with high-risk smoldering multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
Data from the phase 3 MK-3475A-D77 trial support the Japanese approval of subcutaneous pembrolizumab and berahyaluronidase alfa.